Morphine is the mainstay of pain control in cancer patients. We describe three patients in whom adequate analgesia was not obtained with morphine, and discuss the role of morphine metabolites and the use of methadone as an alternative strong opioid analgesic.
Galer BS, Coyle N., Pasternak GW, Portenoy RKIndividual variability in the response to different opioids: report of five cases. Pain1992; 49: 87-91.
2.
McQuay HJ, Carroll D., Faura CC, Gavaghan DJ, Hand CW, Moore RAOral morphine in cancer pain: influences on morphine and metabolite concentration . Clin Pharmacol Ther1990; 48: 236-44.
3.
Venn RF, Machalkiewicz A., Hardy P., Wells C.Concentrations of morphine, morphine metabolites and peptides in human CSF and plasma. Pain1990; 5: S188.
4.
Bowsher D.Paradoxical pain. Br Med J1993; 306: 473.
5.
Paul D., Standifer KM, Inturrisi CE, Pasternak GWPharmacological characterization of morphine-6-glucuronide, a very potent morphine metabolite. J Pharmacol Exp Ther1989; 257: 477-83.
6.
Smith TS, Watt JA, Cramond T.Morphine-3-glucuronide, a potent antagonist of morphine analgesia . Life Sci1990; 47: 579-85.
7.
Gong QL, Hedner J., Bjorkman R., Hedner T.Morphine-3-glucuronide may functionally antagonize morphine-6-glucuronide induced antinociception and ventilatory depression in the rat. Pain1992; 48: 249-55.
8.
Fainsinger R. , Schoeller T., Bruera E.Methadone in the management of cancer pain: a review. Pain1993; 52: 137-47.
